OP
AQST icon

ORG Partners’s Aquestive Therapeutics AQST Stock Holding History

ORG Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$28.9K Buy
4,472
+2,130
+91% +$13.3K 0.01% 707
2025
Q3 		$15.9K Buy
+2,342
New +$10.1K ﹤0.01% 855

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ORG Partners's AQST Position: Q4 2025 in Review

ORG Partners increased its Aquestive Therapeutics (AQST) stake by 91% in Q4 2025, buying an estimated $13.3K and bringing the position to 4,472 shares worth $28.9K. The position accounts for 0.01% of the portfolio, ranked #707.

ORG Partners first reported a position in AQST in Q3 2025 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • ORG Partners held 4,472 shares of Aquestive Therapeutics worth $28.9K as of Q4 2025.
  • ORG Partners bought 2,130 Aquestive Therapeutics shares in Q4 2025, an estimated $13.3K.
  • Aquestive Therapeutics made up 0.01% of ORG Partners's portfolio in Q4 2025, its #707 holding.
  • ORG Partners first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.